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Adipose Tissue Depots and Their Cross-Sectional Associations With
Circulating Biomarkers of Metabolic Regulation
Jane J. Lee, PhD; Kathryn A. Britton, MD; Alison Pedley, PhD; Joseph M. Massaro, PhD; Elizabeth K. Speliotes, MD, PhD, MPH; Joanne M.
Murabito, MD, ScM; Udo Hoffmann, MD; Cheryl Ingram, MD; John F. Keaney, Jr, MD; Ramachandran S. Vasan, BS;* Caroline S. Fox, MD, MPH*
Background-—Visceral adipose tissue (VAT) and fatty liver differ in their associations with cardiovascular risk compared with
subcutaneous adipose tissue (SAT). Several biomarkers have been linked to metabolic derangements and may contribute to the
pathogenicity of fat depots. We examined the association between fat depots on multidetector computed tomography and
metabolic regulatory biomarkers.
Methods and Results-—Participants from the Framingham Heart Study (n=1583, 47% women) underwent assessment of SAT, VAT,
and liver attenuation. We measured circulating biomarkers secreted by adipose tissue or liver (adiponectin, leptin, leptin receptor,
fatty acid binding protein 4, fetuin-A, and retinol binding protein 4). Using multivariable linear regression models, we examined
relations of fat depots with biomarkers. Higher levels of fat depots were positively associated with leptin and fatty acid binding
protein 4 but negatively associated with adiponectin (all P<0.001). Associations with leptin receptor, fetuin-A, and retinol binding
protein 4 varied according to fat depot type or sex. When comparing the associations of SAT and VAT with biomarkers, VAT was the
stronger correlate of adiponectin (b=0.28 [women]; b=0.30 [men]; both P<0.001), whereas SAT was the stronger correlate of
leptin (b=0.62 [women]; b=0.49 [men]; both P<0.001; P<0.001 for comparing VAT versus SAT). Although fetuin-A and retinol
binding protein 4 are secreted by the liver in addition to adipose tissue, associations of liver attenuation with these biomarkers was
not stronger than that of SAT or VAT.
Conclusions-—SAT, VAT, and liver attenuation are associated with metabolic regulatory biomarkers with differences in the
associations by fat depot type and sex. These ﬁndings support the possibility of biological differences between fat depots. ( J Am
Heart Assoc. 2016;5:e002936 doi: 10.1161/JAHA.115.002936)
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O besity is recognized as a heterogeneous condition inwhich persons with similar body mass index (BMI) may
have distinct metabolic and cardiovascular disease risk.1–3
Differences in ectopic fat (fat deposited in nonclassical
locations, such as surrounding the viscera and inﬁltrating the
liver) volume and distribution has been postulated to partially
explain this differential risk.1 Consistent with this premise,
ectopic fat depots, such as visceral adipose tissue (VAT) and
fatty liver, have been more strongly associated with cardiovas-
cular risk factors and cardiometabolic disorders than subcuta-
neous adipose tissue (SAT)4–9; however, the mechanisms
underlying these relationships remain incompletely understood.
Multiple bioactive molecules are believed to contribute to
metabolic and vascular disease.10,11 These include biomarkers
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secreted primarily by adipose tissue only (adiponectin, leptin,
leptin receptor, and fatty acid binding protein 4 [FABP-4]), or
secreted by both adipose tissue and the liver (fetuin-A and
retinol binding protein 4 [RBP-4]). Obesity has been associated
with dysregulation of these biomarkers, with upregulation of
leptin,12 FABP-4,13 and fetuin-A14 and downregulation of
adiponectin15,16 and the leptin receptor.17,18 In addition,
alterations in these biomarkers have been associated with
insulin resistance15,19–24 and with several components of the
metabolic syndrome23–25 or diabetes.26
Levels of certain local and circulating biomarkers have
been shown to vary for different adipose tissue depots27–29;
however, a clear understanding of the development of
cardiometabolic disease manifested by dysfunctional ectopic
fat depots and metabolic regulatory biomarkers has not been
established. Exploring the associations between ectopic
adipose tissue and a broad array of metabolic regulatory
biomarkers in a large population-based study setting may
provide insights into potential links between speciﬁc fat
depots with cardiovascular and metabolic disease.
In this analysis, we sought to determine the associations of
fat depots assessed with multidetector computed tomography
(MDCT), including SAT, VAT, and liver attenuation (an MDCT
surrogate for the amount of fat in the liver), with a panel of
circulating biomarkers previously associated with metabolic
regulation, including adiponectin, leptin, leptin receptor,
FABP-4, fetuin-A, and RBP-4. We also examined the associ-
ation of alanine aminotransferase (ALT) and aspartate amino-
transferase (AST), potential biochemical surrogates for the
presence of nonalcoholic fatty liver disease (NAFLD), and our
biomarker panel.
Methods
Study Sample
Participants from the present study were drawn from the
Framingham Heart Study Third Generation Cohort, which
consists of participants with at least 1 parent enrolled in the
Framingham Offspring Study. Participants for the current
analysis participated in the MDCT substudy. The study
designs were described previously.30,31 From the Third
Generation Cohort, 1994 participants underwent abdominal
MDCT from 2002 to 2005. Of these, 1867 had available
measures for our panel of circulating biomarkers. Among
participants with available biomarker data, 1603 had available
adiposity measures. Of those, 1583 had available covariate
information and were included in the main analysis. We
performed separate analyses examining the associations of
ALT and AST (as surrogate biomarkers of NAFLD) with the
panel of biomarkers. For these analyses, our sample of 1583
participants was restricted to those who had both ALT and
AST data available (n=1546). The institutional review boards
of Boston University and Massachusetts General Hospital
approved the study protocol, and all participants provided
written informed consent.
MDCT Scan Protocol and Adipose Tissue
Measurements
The MDCT scan protocol and adipose tissue depot measure-
ments in the Framingham Heart Study were described
previously.32,33 Participants underwent radiographic assess-
ment of the abdomen in the supine position using an 8-slice
MDCT scanner (LightSpeed Ultra; General Electric), and 25
contiguous slices were reconstructed with a slice thickness of
5 mm without overlap.
Volumetric assessment of fat depots in the Framingham
Heart Study was performed using a dedicated workstation
(Aquarius 3D; TeraRecon), as described previously.32,33
Brieﬂy, the abdominal musculature wall that separates SAT
from VAT was manually traced. Pixels of adipose tissue
were identiﬁed by their characteristic Hounsﬁeld units, and
high-resolution volumetric measurements of SAT and VAT
were deﬁned as the volumetric fat content inside and
outside of this dividing line. Intra- and interreader repro-
ducibility was excellent (>0.99) for SAT and VAT, as
reported previously.32
For liver attenuation, a calibration phantom (Image Analysis
Inc) with a water-equivalent compound (CT-Water, LightSpeed
Ultra; General Electric) and calcium hydroxyapatite at 0, 75,
and 150 mg/cm3 was placed under each participant.33 Three
areas from the liver and 1 from the external phantom were
measured. The average of the liver measurements was
calculated and used to create liver phantom ratios. The liver
phantom ratio reﬂects the relative degree of MDCT liver
attenuation and serves as a surrogate for the amount of fat in
the liver. The intra- and interclass correlation coefﬁcients
were both 0.99, suggesting excellent reproducibility.33
Biomarker Measurements
The biomarker panel included those biomarkers secreted
primarily by adipose tissue (adiponectin, leptin, leptin recep-
tor, and FABP-4) and those secreted by both adipose tissue
and the liver (fetuin-A and RBP-4). Blood samples were drawn
in the morning after participants had fasted overnight, were
immediately centrifuged, and were stored at 80°C without
freeze–thaw cycles until assayed. The average interassay
coefﬁcients of variation for the biomarkers were as follows:
adiponectin, 2.23%; leptin, 4.97%; leptin receptor, 4.01%;
FABP-4, 2.38%; fetuin-A, 2.52%; and RBP-4, 2.18%. Plasma
levels of adiponectin, leptin, leptin receptor, and RBP-4 were
measured using an enzyme-linked immunosorbent assay (R&D
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Systems). Plasma levels of FABP-4 and fetuin-A were
measured using sandwich enzyme-linked immunosorbent
assay (BioVendor Reasearch and Diagnostic Products). ALT
and AST were measured on fasting morning samples using the
kinetic method (Liquid-Stat Reagent Kit; Beckman Coulter).34
Coefﬁcients of variation for ALT and AST were 4.1% to 4.4%
and 3.8% to 4.5%, respectively.
Covariate Assessment
BMI was deﬁned as weight (in kilograms) divided by the
square of the height (in meters). Waist circumference was
measured at the level of the umbilicus. Current smoking was
deﬁned as smoking at least 1 cigarette per day in the year
preceding the Framingham Heart Study examination. Alcohol
use was assessed by physician-administered questionnaires
and dichotomized on the basis of consumption of >7 drinks
per week for women or >14 drinks per week for men. If
menstrual periods had stopped for >1 year, women were
considered postmenopausal. A physical activity index score
was calculated by summing the reported numbers for each
level of activity, weighted by their estimated metabolic
expenditure, as described previously.35 The physical activity
index ranges from a minimum score of 24, indicating
24 hours of sleeping, to a theoretical maximum score of
120, indicating 24 hours of heavy physical activity.
Statistical Analysis
The primary independent variables of interest were SAT, VAT,
and liver attenuation. The primary dependent variables of
interest for all analyses were natural logarithmically trans-
formed adiponectin, leptin, leptin receptor, FABP-4, fetuin-A,
and RBP-4. All analyses were stratiﬁed by sex, given the
known differential association of sex with both fat deposition
and biomarker levels4,36 and because of the signiﬁcant sex
interactions identiﬁed in this study. In addition, test for sex
interaction was conducted based on the pooled model
(women and men combined) to ensure the necessity of
presenting sex-stratiﬁed results.
Partial Pearson correlations (adjusted for age) were
examined to assess relations between adiposity measures
(BMI, waist circumference, SAT, VAT, liver attenuation, ALT
and AST) and biomarkers. Multivariable linear regressions
were performed to assess the association of covariate-
adjusted relations between MDCT adiposity measures (inde-
pendent variables) and levels of circulating biomarkers
(dependent variables). A separate model was performed for
each association tested. All adipose tissue measurements
were standardized within sex to a mean of 0 and an SD of 1.
The b coefﬁcients derived from the regression models
described the association of metabolic regulatory biomarkers
per 1-SD increment in SAT, VAT, or liver attenuation. The
multivariable model included age, smoking status, alcohol use
(>7 drinks/week for women, >14 drinks/week for men),
physical activity index, postmenopausal status (women only),
and use of hormone replacement therapy (women only). In the
secondary analyses, we also adjusted the models for BMI.
The tests for sex interactions were conducted based on the
multivariable model.
Given that SAT and VAT are the largest fat depots, and
both fat depots were signiﬁcantly associated with several
biomarkers, we formally assessed the relative importance of
SAT versus VAT in these associations. We examined models
containing both SAT and VAT by using multivariable regres-
sion analysis. If only 1 fat depot retained statistical signiﬁ-
cance (P<0.008), we considered that fat depot to have the
stronger association. If both fat depots retained statistical
signiﬁcance, we formally tested for the statistical signiﬁcance
of the difference between the SAT and VAT regression
coefﬁcients within a multivariable standardized regression
model. Similarly, the differences of the associations between
VAT and liver attenuation with circulating biomarkers were
examined.
For all regression models, the variance inﬂation factors for
all variables in the models were tested prior to conducting the
regression analysis. Only the variables with variance inﬂation
factor <3, which is below the standard cutoff point of 10
(generally considered problematic), were included in the
regression model because of concerns about multicollinearity.
Secondary Analyses
We explored the associations of ALT and AST as surrogate
biomarkers of NAFLD with circulating biomarkers by con-
structing multivariable linear regression models. We analyzed
ALT and AST as exposures (independent variables) and used
the same covariates in our multivariable linear regressions as
models with MDCT-assessed fat depots. ALT and AST were
natural logarithmically transformed and modeled per 1-SD
increment. ALT and AST were correlated with each other
(r=0.79 and r=0.78 in women and men, respectively;
P<0.001).
All analyses were performed with SAS version 9.2 (SAS
Institute). To account for the presence of multiple biomarkers,
we used a Bonferroni adjusted P value cutoff of <0.008 for
statistical signiﬁcance P value of 0.05 divided by 6 biomarkers
for our main regression analysis. In the regression analysis,
additional adjustment of the P value for multiple testing is
redundant for correlated variables, as it leads the results to be
conservative because of the overadjustment. Consequently,
we did not adjust the P value for multiple testing for the 3
exposures (SAT, VAT, and the liver), given that the fat depots
assessed by MDCT are known to be correlated.4,9
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Results
Study Sample Characteristics
The study sample included 746 women and 837 men with a
mean age of 46.1 and 44.0 years, respectively. Participant
characteristics, including mean levels of SAT, VAT, and liver
attenuation and median levels of biomarkers, are presented in
Table 1.
Correlations of Adiposity Measures and
Biomarkers
In both sexes, there were multiple signiﬁcant correlations of
both anthropometric (BMI, waist circumference) and MDCT
(SAT, VAT, liver attenuation) adiposity measures with
adiponectin, leptin, leptin receptor, and FABP-4 (Table 2). In
general, correlation coefﬁcients between SAT and VAT and
these biomarkers tended to be higher than those between
liver attenuation or serum transaminases (ALT and AST) and
the same biomarkers. Of the biomarkers, leptin and FABP-4
had the highest correlation coefﬁcients with the various fat
depots (BMI, waist circumference, SAT, and VAT) with r values
ranging from 0.72 to 0.80 for leptin (all P<0.001) and from
0.56 to 0.65 for FABP-4 (all P<0.001). There were fewer
statistically signiﬁcant correlations between adiposity mea-
sures and biomarkers secreted by both liver and adipose
tissue (fetuin-A and RBP-4), and the corresponding r values
tended to be lower (Table 2).
Multivariable Associations of MDCT Adiposity
Measures and Biomarkers
In multivariable models, higher volumes of SAT and VAT were
consistently and positively associated with circulating leptin
and FABP-4 levels and negatively associated with adiponectin
and leptin receptor concentrations (all P<0.001) (Table 3).
Table 3 shows a separate model performed for each
association tested. Results for liver attenuation were similar
and directionally consistent, with lower liver attenuation (ie,
more negative attenuation) being associated with a more
adverse proﬁle for these biomarkers. SAT and VAT, but not
liver attenuation, were inversely associated with leptin
receptor. For the biomarkers secreted by both adipose tissue
and the liver (fetuin-A and RBP-4), several multivariable
associations were present, and associations varied according
to the speciﬁc fat depots and participant sex (Table 3).
Sex-Related Differences in Biomarker Associated
With Fat Depots
Associations of the MDCT fat depots with adiponectin, leptin,
FABP-4, and RBP-4 were observed in both sexes but tended to
be stronger in women compared with men (Table 3), partic-
ularly for the associations of SAT and VAT with both
adiponectin and leptin, of VAT with FABP-4, and of liver
attenuation with RBP-4 (all P<0.05 for sex interaction).
Associations between fat depots and leptin receptor were
similar among women and men. For the biomarkers secreted
by both adipose tissue and the liver (fetuin-A and RBP-4),
several associations were limited to 1 sex. Liver attenuation,
for example, was associated with both fetuin-A and RBP-4 in
Table 1. Study Sample Characteristics
Parameters Women (n=746) Men (n=837)
Clinical characteristics
Age, y 46.1 (5.7) 44.0 (6.3)
Smoking (%)
Never 49.5 (369) 59.4 (497)
Former 36.6 (273) 25.4 (213)
Current 13.9 (104) 15.2 (127)
Alcohol use (%)* 14.7 (110) 15.5 (130)
Postmenopausal
status (%)
24.8 (185) —
Hormone replacement
therapy (%)
9.1 (68) —
Physical activity index† 36.4 (6.1) 38.3 (8.9)
Adiposity measures
Body mass index, kg/m2 26.2 (5.9) 27.7 (4.3)
Waist circumference, cm 89.8 (15.5) 98.3 (11.4)
Subcutaneous adipose
tissue, cm3
2937 (1567) 2477 (1166)
Visceral adipose
tissue, cm3
1104 (727) 1924 (872)
Liver phantom ratio‡ 0.36 (0.05) 0.36 (0.06)
Biomarkers§
Adiponectin, lg/mL 10.4 (6.7–15.6) 5.4 (3.5–8.3)
Leptin, ng/mL 13.0 (6.9–26.0) 4.22 (2.6–7.1)
Leptin receptor, ng/mL 18.1 (11.7–24.9) 18.6 (12.0–24.1)
Fatty acid binding
protein 4, ng/mL
19.6 (13.9–27.3) 15.1 (11.2–19.4)
Fetuin-A, mg/L 419.7
(313.3–542.7)
396.6
(311.6–508.2)
Retinol binding
protein 4, ng/mL
37.0 (30.8–44.5) 43.4 (37.5–50.3)
Unless otherwise indicated, data are shown as means (standard deviations) for
continuous variables or proportions (counts) for categorical variables.
*Deﬁned as >7 drinks weekly for women and >14 drinks weekly for men.
†The physical activity index has been previously described.35 The physical activity index
ranges from a minimum score of 24, indicating 24 hours of sleeping, to a maximum
score of 120, indicating 24 hours of heavy physical activity.
‡The liver phantom ratio reﬂects the relative degree of liver attenuation assessed by
multidetector computed tomography and thus serves as a surrogate for the amount of
fat in the liver.
§Described as medians (25th–75th percentiles) because of their skewed distribution.
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women only; SAT was associated with fetuin-A in women only;
and VAT was associated with fetuin-A in men only.
Comparisons Between SAT and VAT
Given that SAT and VAT are the 2 largest fat depots, we
assessed the relative importance of SAT versus VAT in these
associations for instances in which both SAT and VAT were
associated with a given biomarker. In these analyses, notable
differences in associations included the ﬁnding that SAT was
more strongly associated with leptin, whereas VAT was more
strongly associated with adiponectin (Table 4). Associations
of SAT and VAT with leptin receptor and FABP-4 tended to be
similar.
Comparison Between VAT and Liver Attenuation
When both VAT and liver attenuation were individually
associated with biomarkers in multivariable models, we
evaluated both fat depots in the same model. Generally,
VAT was more likely to remain signiﬁcantly associated with a
given biomarker when both fat depots were included in the
model. In some cases, both VAT and liver attenuation
remained associated with a given biomarker (adiponectin
and leptin in women and adiponectin in men) when both fat
depots were included in the same model, and formal
comparison demonstrated a stronger association for VAT
compared with liver attenuation. In women, the b coefﬁcients
for adiponectin were 0.23 (95% CI 0.27 to 0.19) for VAT
and 0.06 (95% CI 0.02–0.10) for liver attenuation (P≤0.001 for
comparison), and the b coefﬁcients for leptin were 0.67 (95%
CI 0.62–0.73) for VAT and 0.07 (95% CI 0.02–0.12) for liver
attenuation (P<0.001 for comparison). For men, the b
coefﬁcients for adiponectin were 0.20 (95% CI 0.25 to
0.16) for VAT, and 0.08 (95% CI 0.04–0.13) for liver
attenuation (P<0.001 for comparison).
Adjustment for BMI
The associations between VAT and liver attenuation with
circulating biomarkers while additionally adjusting for BMI as
a measure of generalized adiposity are shown in Table S1.
Both VAT and liver attenuation remained signiﬁcantly associ-
ated with several biomarkers, although the b coefﬁcients were
generally attenuated, indicating that these associations are
not solely due to the contribution of BMI. Models with SAT as
the exposure were not adjusted for BMI because of concerns
about multicollinearity.4
Multivariable Associations of ALT and AST and
Biomarkers
In multivariable models, both ALT and AST were associated
with several biomarkers (Table S2). In general, ALT was
Table 2. Age-Adjusted Pearson Correlation Coefﬁcients Between Adiposity Measures and Biomarkers of Metabolic Dysregulation
Log Biomarker
Body
Mass Index
Waist
Circumference
Subcutaneous
Adipose Tissue
Visceral Adipose
Tissue
Liver
Attenuation*
Log Alanine
Aminotransferase†
Log Aspartate
Aminotransferase†
Women (n=746)
Adiponectin 0.34§ 0.34§ 0.31§ 0.43§ 0.23§ 0.12‡ 0.07
Leptin 0.76§ 0.75§ 0.80§ 0.69§ 0.17§ 0.10‡ 0.10‡
Leptin receptor 0.24§ 0.23§ 0.23§ 0.23§ 0.04 0.04 0.14§
Fatty acid binding protein 4 0.64§ 0.63§ 0.64§ 0.65§ 0.23§ 0.23§ 0.08
Fetuin-A 0.12‡ 0.12‡ 0.10‡ 0.09‡ 0.11‡ 0.10‡ 0.03
Retinol binding protein 4 0.04 0.07‡ 0.07 0.09‡ 0.13§ 0.06 0.09
Men (n=837)
Adiponectin 0.26§ 0.23§ 0.13§ 0.35§ 0.25§ 0.21§ 0.01
Leptin 0.72§ 0.77§ 0.79§ 0.67§ 0.27§ 0.30§ 0.08
Leptin receptor 0.21§ 0.23§ 0.22§ 0.22§ 0.03 0.01 0.10‡
Fatty acid binding protein 4 0.56§ 0.60§ 0.57§ 0.58§ 0.26§ 0.26§ 0.12§
Fetuin-A 0.09‡ 0.10‡ 0.05 0.11‡ 0.06 0.11‡ 0.10‡
Retinol binding protein 4 0.03 0.06 0.01 0.16§ 0.07 0.19§ 0.15§
*Liver attenuation is represented by the natural log-transformed liver phantom ratio.
†The sample size for the alanine and aspartate aminotransferase analyses (n=727 for women and n=819 for men) was slightly smaller because the sample included participants with all
available fat depots plus alanine and aspartate aminotransferase measurements.
‡Designates P<0.01.
§Designates P<0.001.
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associated with more biomarkers than AST. For biomarkers
secreted by adipose tissue, ALT appeared to generally mirror
the associations between MDCT liver attenuation and these
biomarkers. In contrast, associations between ALT and AST
and biomarkers secreted by both adipose tissue and the liver
did not mirror those of liver attenuation.
Table 3. Multivariable* Regression Models for Relations Between Fat Depots and Biomarkers of Metabolic Regulation
Log Biomarker
Subcutaneous Adipose Tissue Visceral Adipose Tissue Liver Attenuation†
b (95% CI) P Value‡ b (95% CI) P Value‡ b (95% CI) P Value‡
Women
Adiponectin 0.18 (0.23 to 0.14)§ <0.001 0.25 (0.29 to 0.21)§ <0.001 0.13 (0.09–0.17) <0.001
Leptin 0.74 (0.70–0.78)§ <0.001 0.65 (0.60–0.70)§ <0.001 0.14 (0.21 to 0.08) <0.001
Leptin receptor 0.10 (0.13 to 0.06) <0.001 0.10 (0.13 to 0.07) <0.001 0.02 (0.02 to 0.05) 0.4
Fatty acid binding protein 4 0.30 (0.27–0.33) <0.001 0.31 (0.28–0.34)§ <0.001 0.10 (0.13 to 0.07) <0.001
Fetuin-A 0.04 (0.01–0.07) 0.004 0.04 (0.01–0.07) 0.008 0.05 (0.08 to 0.02) 0.001
Retinol binding protein 4 0.02 (0.004–0.04) 0.02 0.03 (0.008–0.05) 0.006 0.03 (0.05 to 0.01)§ <0.001
Men
Adiponectin 0.08 (0.12 to 0.04)§ <0.001 0.24 (0.28 to 0.20)§ <0.001 0.17 (0.12 to 0.21) <0.001
Leptin 0.65 (0.61–0.68)§ <0.001 0.58 (0.53–0.62)§ <0.001 0.22 (0.28 to 0.17) <0.001
Leptin receptor 0.10 (0.13 to 0.07) <0.001 0.11 (0.14 to 0.07) <0.001 0.02 (0.02 to 0.05) 0.3
Fatty acid binding protein 4 0.25 (0.23–0.28) <0.001 0.27 (0.24–0.29)§ <0.001 0.11 (0.14 to 0.09) <0.001
Fetuin-A 0.02 (0.01 to 0.04) 0.2 0.04 (0.02–0.07) 0.001 0.02 (0.05 to 0.002) 0.07
Retinol binding protein 4 0.002 (0.01 to 0.02) 0.7 0.03 (0.02–0.05) <0.001 0.01 (0.03 to 0.004)§ 0.2
Data are shown as b coefﬁcients per 1-SD increment of each fat measure. Fat depots were sex standardized to a mean of 0 and an SD of 1.
*Multivariable models adjusted for age, smoking status, alcohol use, physical activity index, postmenopausal status (women only), and hormone replacement therapy (women only).
†Liver attenuation is represented by the natural log-transformed liver phantom ratio.
‡Bonferroni corrected P<0.008 P value of 0.05 divided by 6 biomarkers was considered statistically signiﬁcant.
§Signiﬁcant sex interaction was present (P<0.05 for sex interaction) with association stronger in women compared with men.
Table 4. Comparison of the Associations of Subcutaneous Versus Visceral Adipose Tissue and Biomarkers of Metabolic Regulation
Based on the Multivariable* Regression Models
Log Biomarker†
Subcutaneous Adipose Tissue Visceral Adipose Tissue
P Difference‡b (95% CI) P Value b (95% CI) P Value
Women
Adiponectin 0.04 (0.03 to 0.10) 0.3 0.28 (0.35 to 0.22) <0.001 §
Leptin 0.62 (0.56–0.69) <0.001 0.15 (0.08–0.21) <0.001 <0.001
Leptin receptor 0.05 (0.11 to 0.001) 0.05 0.06 (0.11 to 0.001) 0.05 ||
Fatty acid binding protein 4 0.16 (0.12–0.20) <0.001 0.18 (0.14–0.22) <0.001 0.5
Men
Adiponectin 0.09 (0.04–0.14) <0.001 0.30 (0.35 to 0.25) <0.001 <0.001
Leptin 0.49 (0.45–0.53) <0.001 0.27 (0.23–0.32) <0.001 <0.001
Leptin receptor 0.06 (0.10 to 0.02) 0.002 0.07 (0.11 to 0.03) <0.001 0.9
Fatty acid binding protein 4 0.16 (0.13–0.19) <0.001 0.17 (0.14–0.20) <0.001 0.7
Data are shown as b coefﬁcients per 1-SD increment of each fat measure. Fat depots were sex standardized to a mean of 0 and a SD of 1.
*Multivariable models adjusted for age, smoking status, alcohol use, physical activity index, postmenopausal status (women only), and hormone replacement therapy (women only). The
subcutaneous adipose tissue model was additionally adjusted for visceral adipose tissue volume, and the visceral adipose tissue model was additionally adjusted for subcutaneous adipose
tissue volume.
†Fetuin-A and retinol binding protein 4 were excluded from this analysis because both of those biomarkers were signiﬁcantly associated only with visceral adipose tissue.
‡The P difference reﬂects formal comparison between the strength of the association of subcutaneous adipose tissue vs visceral adipose tissue and biomarkers.
§Not tested because only visceral adipose tissue was signiﬁcantly associated with the biomarker in models that contained both fat depots.
||Not tested because neither fat depot was signiﬁcantly associated with the biomarker when both fat depots were included in the multivariable model.
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Discussion
Principal Findings
In our community-based sample, SAT, VAT, and surrogate
biomarkers of NAFLD, including MDCT liver attenuation and
circulating transaminases, were associated with multiple
biomarkers of metabolic regulation with differences in the
associations by fat depot type and sex. SAT and VAT tended
to be more strongly associated with our biomarker panel than
our surrogate measures for NAFLD or liver attenuation. These
stronger associations for SAT and VAT generally extended not
only to biomarkers secreted by adipose tissue (adiponectin,
leptin, leptin receptor, and FABP-4) but also to those
biomarkers secreted by both adipose tissue and the liver
(fetuin-A and RBP-4). Comparison of the strength of the
associations between SAT and VAT demonstrated several
differential associations. Speciﬁcally, SAT demonstrated
stronger associations with leptin, whereas VAT demonstrated
stronger associations with adiponectin. Taken together, these
ﬁndings support further investigation into potential biological
differences between these fat depots.
In the Context of the Current Literature
The sexual dimorphism in respect to the association between
fat depots and adipokines are well established by prior
studies. Compared with men, higher circulating levels of
adiponectin37,38 and leptin37,39,40 were observed in women,
even in a matched pair of similar age, BMI, insulin sensitivity,
and VAT volume38 or mean fat size.39 The disparities in the
functions of adipokines are also noted in the literature.41,42 In
this current research, signiﬁcant sex interactions with several
biomarkers were identiﬁed, with stronger associations noted
in women. These circulating levels and the functions of certain
adipokines may be sexually dimorphic because of the
differences in the amount of total and regional body fat
distribution or the relations of sex steroids and circulating
biomarkers.43
Cross-sectional associations have been reported between
fat depots and cardiometabolic risk factors,4,9,44,45 with
associations tending to vary by the type of fat depot.4,6
Adipokines, bioactive substances secreted by adipose tissue,
have been postulated as potential mediators of these
associations,1–3 and several epidemiological studies have
examined associations between fat depots and individual
adipokines46–48 and between adipokines and cardiometabolic
disease.15,19–26 No study, however, compared the relative
associations of MDCT-derived fat measures (SAT, VAT, and
liver attenuation) with a comprehensive list of metabolic
regulatory biomarkers. In particular, prior human studies of
fatty liver and adipokines have primarily examined individual
biomarkers and often have had small sample sizes or been
limited to patients with NAFLD and matched controls.44,49–52
In general, VAT and fatty liver have been more strongly
associated with individual biomarkers of metabolic regulation
compared with anthropometric measures or subcutaneous
fat.46,53 A recent study of 2215 multiethnic participants
showed signiﬁcant associations between hepatic triglyceride
content and VAT with adiponectin (all P<0.01).47 In that study,
the association with SAT and adiponectin was not signiﬁcant
after additionally adjustment for hepatic triglyceride content
and VAT (P<0.05).47 In another study of 102 healthy Korean
women, VAT but not SAT was identiﬁed as an independent
predictor of RBP-4 based on a multiple regression model.29
In this analysis, we observed associations between liver
attenuation and multiple biomarkers, including adiponectin,
leptin, and FABP-4. We also added to the relatively small
number of studies that have compared the relative strength of
the associations of measures of liver fat in comparison with
VAT. In contrast to the previous studies including the Dallas
Heart Study47 and a study of 242 nondiabetic white
participants54 that measured intrahepatic fat by magnetic
resonance spectroscopy, we found a stronger association of
VAT with adiponectin compared with liver attenuation. This
difference may be related to distinct patient populations and
different modalities for assessing intrahepatic fat. Our study
showed high precision of abdominal SAT, VAT, and liver
attenuation using the computed tomography imaging tech-
nique.32,33 In addition, computed tomography imaging is
considered a gold standard for quantifying abdominal SAT and
VAT, conﬁrming the accuracy of our abdominal fat measure-
ment. In contrast, the liver phantom ratio that was used in our
study as a measure of liver fat is a proxy for liver fat content.
Speciﬁcally, the Dallas Heart Study measure of intrahepatic
fat using magnetic resonance spectroscopy is considered a
gold standard among the noninvasive measures of liver
fat.47,55 Collectively, the methodological differences in the
assessment of liver fat could lead to misclassiﬁcation and
would tend to bias our results related to liver attenuation
toward the null. In addition, the physiological differences
between the study participants assessed by different fat
assessment techniques may have yielded different ﬁndings
depending on the characteristics of the study population.
Consistent with experimental and epidemiological studies
suggesting differences in local and circulating adipokine levels
between SAT and VAT,27,28,46 we found differential associa-
tions of SAT and VAT with certain, but not all, biomarkers. In
particular, our results regarding fat depot–speciﬁc associa-
tions of VAT with adiponectin and SAT with leptin were
consistent with the ﬁndings of previous studies.36,38,46,56–60
This present study adds to the growing body of literature
supporting the differential associations between speciﬁc fat
depots and a wide panel of circulating biomarkers based on a
population-based setting with a larger sample size. In addition,
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we added to the existing literature by examining the
associations between measures of fatty liver with adipokines,
including those secreted by both adipose tissue and the liver.
Potential Mechanisms
The circulating biomarkers explored in this study modulate a
broad range of physiological functions, including glucose
homeostasis, lipid metabolism, energy expenditure, hemosta-
sis, and inﬂammatory and immune responses.10,11 Higher
levels of adiponectin have been associated with hepatoprotec-
tive and antisteatotic properties, along with antioxidative,
insulin-sensitizing, and antiatherogenic effects.61,62 Leptin is
involved with regulation of a broad property, such as
hematopoiesis, maturation, bone metabolism, appetite, and
satiety control, which is signaled via binding with leptin
receptors.63 Upregulated leptin is associated with reduction in
the hypothalamic levels of leptin receptor and deterioration of
the transduction signals of the leptin. FABP-4 is essential for
fatty acid trafﬁcking, adipocyte inﬂammation, and insulin action
by binding with fatty acid and interacting with hormone-
sensitivity lipase.64 Fetuin-A is dominantly secreted from the
liver, and elevated levels of fetuin-A increase insulin resistance
by interfering with the activity of insulin receptor tyrosine
kinase in the muscle and the liver.65 RBP-4 is associated with
regulation of insulin responses and lipid hemostasis and is
predominantly produced by the liver; however, between SAT
and VAT, the release is more active in VAT.48
Underlying mechanisms that might explain the differential
associations of speciﬁc fat depots with circulating biomarkers
of metabolic regulation remain speculative. A possibility is
that circulating biomarkers may reﬂect differential local
secretion of these biomarkers in speciﬁc fat depots. Accu-
mulating evidence supports underlying structural and func-
tional differences between fat depots, including differences in
cellularity, adipocyte metabolism, and extracellular matrix
composition,66 that may contribute to differential secretion of
adipokines. These local biomarkers may then inﬂuence a
myriad of pathways important for the development of
metabolic and cardiovascular disease, including inﬂammation
and angiogenesis.10 Nevertheless, this explanation, which
links circulating and local biomarkers, may be overly simplistic
because circulating biomarkers generally reﬂect only a
proportion of total adipokine secretion and may not reﬂect
their local autocrine and paracrine action. Furthermore,
adipose tissue serves as both a source and a target of
adipokines, making it difﬁcult to untangle the likely complex
biological relationship between fat depots and adipokines.10
Alternatively, aberrations in circulating adipokine levels may
reﬂect systemic metabolic changes. An emerging body of
literature suggests that accumulation of visceral and liver fat
may actually serve as a marker of dysfunctional SAT,67 and it
is the inability of SAT to respond to positive energy balance
that concomitantly results in dysregulation of adipokines and
systemic metabolic changes.68
Strengths and Limitations
Strengths of our study include a well-characterized community-
based sample with sophisticated assessment adipose tissue
depots by MDCT and a broad panel of circulating biomarkers of
metabolic regulation. Given our relatively large sample size, we
were able to sex-stratify our results and demonstrate several
differential associations in women compared with men. These
ﬁndings are relevant, given the previously reported sex
differences in associations between fat depots and cardiovas-
cular risk factors.4 Some limitations deserve comment. First,
our sample is predominantly white, which may limit general-
izability to other ethnic groups. Second, the cross-sectional
design of the analysis prevents inferences of causality or
temporality. Next, repeated measures of MDCT-assessed
adipose tissue depots were not available. Accordingly, we were
unable to calculate error correction coefﬁcients from the data
used in our study. Finally, given that our biomarkers are
circulating, the lack of associations between certain fat depots
and adipokines does not exclude an association with local
levels of these biomarkers.
Conclusion
Multiple adipose tissue depots, including SAT, VAT, and
surrogate markers of NAFLD, demonstrated associations with
circulating biomarkers of metabolic regulation secreted by
adipose tissue only or by both adipose tissue and the liver.
The magnitude of these associations varied by fat depot type
and sex. These ﬁndings support further investigation into
potential biological differences among these fat depots.
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SUPPLEMENTAL MATERIAL 
 
 
 
   Table S1. Multivariable
* plus BMI adjusted regression models for relations between fat depots and biomarkers of 
metabolic regulation. Data are shown as β coefficients per 1 standard deviation increment of fat measure. Fat depots 
were sex-standardized to a mean of 0 and a standard deviation of 1.     
Log-Biomarker 
Visceral Adipose Tissue  Liver Attenuation† 
β (95% CI) p-Value  β (95% CI) p-Value 
Women      
Adiponectin -0.29 (-0.36, -0.21) < 0.001  0.10 (0.06, 0.14) < 0.001 
Leptin 0.18 (0.10, 0.26) < 0.001  0.003 (-0.04, 0.05) 0.9 
Leptin Receptor -0.04 (-0.10, 0.02) 0.2  -0.01 (-0.04, 0.03) 0.7 
Fatty Acid Binding Protein-4 0.18 (0.13, 0.23) < 0.001  -0.04 (-0.07, -0.01) 0.005 
Fetuin-A 0.001 (-0.05, 0.06) 0.98  -0.04 (-0.07, -0.01) 0.01 
Retinol Binding Protein-4 0.04 (0.01, 0.08) 0.02  -0.04 (-0.05, -0.01) 0.002 
      
Men      
Adiponectin -0.25 (-0.32, -0.19) < 0.001  0.12 (0.08, 0.17) < 0.001 
Leptin 0.26 (0.20, 0.32) < 0.001  -0.02 (-0.07, 0.02) 0.2 
Leptin Receptor -0.07 (-0.12, -0.03) 0.003  -0.02 (-0.05, 0.01) 0.3 
Fatty Acid Binding Protein-4 0.16 (0.12, 0.20) < 0.001  -0.03 (-0.06, -0.01) 0.01 
Fetuin-A 0.04 (0.001, 0.08) 0.04  -0.01 (-0.04, 0.01) 0.3 
Retinol Binding Protein-4 0.07 (0.04, 0.09) < 0.001  -0.01 (-0.03, 0.01) 0.2 
*Multivariable models adjusted for age, smoking status, alcohol use, physical activity index, postmenopausal status 
(women only), and hormone replacement therapy (women only). 
†Liver attenuation is represented by the natural log-transformed liver-phantom ratio.  
Abbreviations: BMI, body mass index; CI, confidence Interval. 
  
 
 
Table S2. Multivariable* regression models for relations between natural log-transformed alanine aminotransferase and aspartate aminotransferases with biomarkers 
of metabolic regulation. Data are shown as β coefficients per 1 standard deviation increment of each natural log-transformed aminotransferase. 
Log-Biomarker 
Alanine Aminotransferase  Aspartate Aminotransferases 
Multivariable Model  Multivariable + BMI Model  Multivariable Model  Multivariable + BMI Model 
β (95% CI) p-Value  
 
β (95% CI) p-Value  β (95% CI) p-Value  
 
β (95% CI) p-Value 
Women            
Adiponectin  -0.07 (-0.11, -0.02) 0.003  -0.03 (-0.07, 0.02) 0.2    0.04 (-0.004, 0.08) 0.08  0.04 (0.001, 0.08) 0.05 
Leptin 0.10 (0.03, 0.17) 0.003     -0.05 (-0.10, -0.004) 0.03     -0.09 (-0.16, -0.02) 0.01   -0.10 (-0.14, -0.06) < 0.001 
Leptin Receptor  0.01 (-0.02, 0.05) 0.4   0.04 (0.003, 0.07) 0.03  0.06 (0.02, 0.09) 0.001  0.06 (0.03, 0.09) < 0.001 
FABP-4 0.11 (0.07, 0.14) < 0.001  0.05 (0.02, 0.07) 0.001  0.04 (0.002, 0.07) 0.04  0.03 (0.006, 0.060) 0.02 
Fetuin-A 0.05 (0.02, 0.08) 0.003    0.04 (0.006, 0.07) 0.02  0.01 (-0.02, 0.04) 0.4  0.01 (-0.02, 0.04) 0.4 
RBP-4  0.01 (-0.01, 0.03) 0.1     0.01 (-0.008, 0.03) 0.2    0.02 (-0.003, 0.04) 0.1  0.02 (-0.003, 0.04) 0.1 
            
Men            
Adiponectin  -0.14 (-0.18, -0.09) < 0.001   -0.09 (-0.14, -0.05) < 0.001  -0.01 (-0.05, 0.04) 0.8  0.02 (-0.03, 0.06) 0.4 
Leptin 0.26 (0.20, 0.31) < 0.001  0.07 (0.03, 0.11) 0.002  0.07 (0.01, 0.13) 0.02 -0.01 (-0.05, 0.03) 0.5 
Leptin Receptor  -0.01 (-0.04, 0.03) 0.7     0.03 (-0.005, 0.06) 0.09  0.04 (0.01, 0.08) 0.01  0.06 (0.03, 0.09) < 0.001 
FABP-4 0.12 (0.09, 0.15) < 0.001  0.04 (0.01, 0.07) 0.003  0.06 (0.03, 0.09) <0.001  0.02 (-0.002, 0.05) 0.08 
Fetuin-A 0.05 (0.02, 0.07) <0.001  0.04 (0.01, 0.07) 0.003  0.04 (0.02, 0.07) 0.001  0.04 (0.01, 0.07) 0.003 
RBP-4 0.04 (0.02, 0.05) < 0.001  0.04 (0.02, 0.05) < 0.001  0.03 (0.01, 0.04) <0.001  0.03 (0.01, 0.04) < 0.001 
* Multivariable models adjusted for age, alcohol use, smoking status, physical activity index, postmenopausal status (women only), and hormone replacement 
therapy (women only). 
Abbreviations: BMI, body mass index; CI, confidence Interval; FABP-4, fatty acid binding protein-4; RBP-4, retinol binding protein-4. 
 
